Ron Bentsur Nuvectis Pharma, Inc. (NVCT) insider trading activity

NVCT Quotes by TradingView

Ron Bentsur is Chairman & CEO of Nuvectis Pharma, Inc.. Currently has a direct ownership of 3.27 Million shares of NVCT, which is worth approximately $16.6 Million. The most recent transaction as insider was on Jun 28, 2022, when has been sold 300 shares (Common Stock) at a price of $11.82 per share, resulting in proceeds of $3,546. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.27M
0.62% 3M change
0.89% 12M change
Total Value Held $16.6 Million

RON BENTSUR Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 28 2022
BUY
Open market or private purchase
$3,546 $11.82 p/Share
300 Added 0.01%
2,964,614 Common Stock
Jun 24 2022
BUY
Open market or private purchase
$4,872 $12.18 p/Share
400 Added 0.01%
2,964,314 Common Stock
Jun 23 2022
BUY
Open market or private purchase
$2,280 $11.4 p/Share
200 Added 0.01%
2,963,914 Common Stock
Jun 22 2022
BUY
Open market or private purchase
$1,310 $13.1 p/Share
100 Added 0.0%
2,963,714 Common Stock
May 27 2022
BUY
Open market or private purchase
$7,870 $15.74 p/Share
500 Added 0.02%
2,963,614 Common Stock
May 26 2022
BUY
Open market or private purchase
$7,950 $15.9 p/Share
500 Added 0.02%
2,963,114 Common Stock
May 20 2022
BUY
Open market or private purchase
$16,280 $16.28 p/Share
1,000 Added 0.03%
2,962,614 Common Stock
May 19 2022
BUY
Open market or private purchase
$3,790 $18.95 p/Share
200 Added 0.01%
2,961,614 Common Stock
May 18 2022
BUY
Open market or private purchase
$33,235 $19.55 p/Share
1,700 Added 0.06%
2,961,414 Common Stock
May 17 2022
BUY
Open market or private purchase
$6,293 $20.3 p/Share
310 Added 0.01%
2,959,714 Common Stock
May 16 2022
BUY
Open market or private purchase
$19,320 $19.32 p/Share
1,000 Added 0.03%
2,959,404 Common Stock
May 13 2022
BUY
Open market or private purchase
$12,670 $18.1 p/Share
700 Added 0.02%
2,958,404 Common Stock
May 12 2022
BUY
Open market or private purchase
$197,022 $16.09 p/Share
12,245 Added 0.41%
2,957,704 Common Stock
Apr 01 2022
BUY
Grant, award, or other acquisition
-
120,000 Added 3.91%
2,945,459 Common Stock
Mar 28 2022
BUY
Open market or private purchase
$28,200 $7.05 p/Share
4,000 Added 0.14%
2,825,459 Common Stock, par valu...
Mar 17 2022
BUY
Open market or private purchase
$53,410 $7.63 p/Share
7,000 Added 0.25%
2,821,459 Common Stock, par valu...
Feb 14 2022
BUY
Open market or private purchase
$47,040 $5.88 p/Share
8,000 Added 0.28%
2,814,459 Common Stock, par valu...
Feb 10 2022
BUY
Open market or private purchase
$53,890 $6.34 p/Share
8,500 Added 0.3%
2,806,459 Common Stock, par valu...
Feb 07 2022
BUY
Open market or private purchase
$121,800 $6.09 p/Share
20,000 Added 0.71%
2,797,959 Common Stock, par valu...
Feb 04 2022
BUY
Open market or private purchase
$945,625 $4.45 p/Share
212,500 Added 7.11%
2,777,959 Common Stock, par valu...

Also insider at

XAIR
Beyond Air, Inc. Healthcare
Director
RB

Ron Bentsur

Chairman & CEO
Garden City, NY

Track Institutional and Insider Activities on NVCT

Follow Nuvectis Pharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NVCT shares.

Notify only if

Insider Trading

Get notified when an Nuvectis Pharma, Inc. insider buys or sells NVCT shares.

Notify only if

News

Receive news related to Nuvectis Pharma, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on NVCT